{
    "nctId": "NCT00082667",
    "briefTitle": "Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast",
    "officialTitle": "EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1,
    "primaryOutcomeMeasure": "Compare epidermal growth factor receptor (EGFR) pathway biomarker modulation in tissue samples of women with ductal carcinoma in situ (DCIS) of the breast treated with gefitinib vs placebo followed by surgery.",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed ductal carcinoma in situ (DCIS) of the breast OR mammogram highly suspicious for DCIS\n\n  * No invasive disease\n  * Not completely excised\n* Epidermal growth factor receptor (EGFR) positive (\\> 10% of cells stained)\n* Planned lumpectomy or mastectomy within the next 2-4 weeks\n* Hormone receptor status:\n\n  * Estrogen receptor status known\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 35 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Granulocyte count \\> 1,500/mm\\^3\n* Platelet count \\> 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin \\< 1.5 mg/dL\n* SGOT \u2264 2 times upper limit of normal (ULN)\n* SGPT \\< 1.5 times ULN\n* PT and PTT \u2264 1.5 times ULN\n* INR \u2264 1.5 times ULN\n\nRenal\n\n* Creatinine \\< 1.5 mg/dL\n\nCardiovascular\n\n* No New York Heart Association class I-IV heart disease\n\nPulmonary\n\n* No acute asthma\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Random blood sugar \\< 2.5 times ULN\n* No known hypersensitivity to study drug or its excipients\n* No nonhealing wound or fracture\n* No active infection\n* No other malignancy within the past 5 years except basal cell carcinoma, breast carcinoma, or carcinoma in situ of the cervix\n* No psychosis or severe depression\n* No other concurrent uncontrolled illness\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No prior trastuzumab (Herceptin\u00ae)\n\nChemotherapy\n\n* At least 1 year since prior chemotherapy\n* No concurrent chemotherapy\n\nEndocrine therapy\n\n* At least 1 year since prior aromatase inhibitors\n* At least 1 year since prior antiestrogens or luteinizing hormone-releasing hormone agonists or antagonists\n* No concurrent glucocorticoids\n* Concurrent oral contraceptives allowed\n* Concurrent hormone replacement therapy allowed\n\nRadiotherapy\n\n* At least 1 year since prior radiotherapy\n* No concurrent radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n* Recovered from prior oncologic or other major surgery\n* No prior organ allograft\n\nOther\n\n* Recovered from all prior therapy (except alopecia)\n* More than 30 days since prior non-approved or investigational drugs\n* No prior definitive local therapy\n* No prior immunosuppressive therapy\n* No prior gefitinib\n* No other prior EGFR inhibitors\n* No other concurrent cytotoxic drugs\n* No concurrent warfarin for anticoagulation\n* No concurrent CYP3A4 inducers, including any of the following:\n\n  * Phenytoin\n  * Carbamazepine\n  * Barbiturates\n  * Rifampin\n  * Phenobarbital\n  * Hypericum perforatum (St. John's wort)\n  * Ethosuximide\n  * Griseofulvin\n  * Nafcillin\n  * Nelfinavir\n  * Nevirapine\n  * Oxcarbazepine\n  * Phenylbutazone\n  * Primidone\n  * Rifabutin\n  * Rofecoxib\n  * Sulfamethazine\n  * Sulfinpyrazone\n  * Troglitazone\n* No concurrent antiretroviral treatment for HIV-positive patients",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}